CoChat

Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases

Open access

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were initially approved for type 2 diabetes mellitus. Recent evidence suggests their therapeutic potential in various diseases, though their efficacy and safety remain incompletely understood. Here, we conduct an umbrella review including 123 meta-analyses covering 464 outcomes from 5617 articles to comprehensively assess the effectiveness and adverse events (AEs) of GLP-1 RAs across diverse outcomes. GLP-1 RAs showed trends toward improvements in endocrine and metabolic, cardiovascular, renal, and respiratory outcomes, cognitive function, with a potential reduction in fracture risk and all-cause mortality in certain populations. However, increased risks of certain AEs, including diabetic retinopathy, ketoacidosis, gastrointestinal events, and treatment discontinuation, were also observed. AMSTAR 2 assessments indicate that the existing evidence is limited by methodological shortcomings, including incomplete reporting of excluded studies, suboptimal literature search strategies, and insufficient evaluation of how bias in primary studies may influence meta-analytic estimates. Some outcomes did not reach statistical significance in all populations, highlighting the need for further high-quality clinical research. Careful consideration of potential benefits and risks is essential for optimizing treatment outcomes and ensuring patient safety when using GLP-1 RAs in clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-025-67701-9

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 PRISMA flow diagram of the study selection process. Flow diagram illustrating the identification, screening, eligibility assessment, and inclusion of studies in the meta-analyses, in accordance with the PRISMA guidelines. PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses, GLP-1 RAs glucagon-like peptide-1 receptor agonists, PICOs Participants, Interventions, Comparisons, Outcomes, and Study design.
Fig. 1 PRISMA flow diagram of the study selection process. Flow diagram illustrating the identification, screening, eligibility assessment, and inclusion of studies in the meta-analyses, in accordance with the PRISMA guidelines. PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses, GLP-1 RAs glucagon-like peptide-1 receptor agonists, PICOs Participants, Interventions, Comparisons, Outcomes, and Study design.CC BY-NC-ND · PubMed Central
Fig. 2 Overall effects of GLP-1 RAs on endocrine and metabolic outcomes. All included meta-analyses were based on RCTs and analyzed using random-effects models. All statistical tests were two-sided, and no adjustments were made for multiple comparisons. Effect estimates are shown as pooled effect sizes with 95% confidence intervals. NR not reported, IG intervention group, CG control group, VL Very Low, L Low, M Moderate, H High, NAFLD nonalcoholic fatty liver disease, NASH nonalcoholic steatohepatitis, MAFLD metabolic dysfunction–associated fatty liver disease, T2DM type 2 diabetes mellitus, PCOS polycystic ovary syndrome, AD Alzheimer’s disease, MCI mild cognitive impairment, DKA diabetic ketoacidosis, ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, HbA1c hemoglobin A1c, IHA intrahepatic fat accumulation, LFC liver fat content.
Fig. 2 Overall effects of GLP-1 RAs on endocrine and metabolic outcomes. All included meta-analyses were based on RCTs and analyzed using random-effects models. All statistical tests were two-sided, and no adjustments were made for multiple comparisons. Effect estimates are shown as pooled effect sizes with 95% confidence intervals. NR not reported, IG intervention group, CG control group, VL Very Low, L Low, M Moderate, H High, NAFLD nonalcoholic fatty liver disease, NASH nonalcoholic steatohepatitis, MAFLD metabolic dysfunction–associated fatty liver disease, T2DM type 2 diabetes mellitus, PCOS polycystic ovary syndrome, AD Alzheimer’s disease, MCI mild cognitive impairment, DKA diabetic ketoacidosis, ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, HbA1c hemoglobin A1c, IHA intrahepatic fat accumulation, LFC liver fat content.CC BY-NC-ND · PubMed Central
Fig. 3 Overall effects of GLP-1 RAs on cardiovascular outcomes. All included meta-analyses were based on RCTs and analyzed using random-effects models. All statistical tests were two-sided, and no adjustments were made for multiple comparisons. Effect estimates are shown as pooled effect sizes with 95% confidence intervals. Symbols (*) and (F) within the figure refer to additional details explained directly in the panel. (NR not reported, IG intervention group, CG control group, VL very low, L low, M moderate, H high, CVD cardiovascular disease, CAD coronary artery disease, CKD chronic kidney disease, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus, HF heart failure, MACE major adverse cardiovascular events, MI myocardial infarction, LVEF left ventricular ejection fraction, SBP systolic blood pressure, LDL low-density lipoprotein cholesterol.
Fig. 3 Overall effects of GLP-1 RAs on cardiovascular outcomes. All included meta-analyses were based on RCTs and analyzed using random-effects models. All statistical tests were two-sided, and no adjustments were made for multiple comparisons. Effect estimates are shown as pooled effect sizes with 95% confidence intervals. Symbols (*) and (F) within the figure refer to additional details explained directly in the panel. (NR not reported, IG intervention group, CG control group, VL very low, L low, M moderate, H high, CVD cardiovascular disease, CAD coronary artery disease, CKD chronic kidney disease, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus, HF heart failure, MACE major adverse cardiovascular events, MI myocardial infarction, LVEF left ventricular ejection fraction, SBP systolic blood pressure, LDL low-density lipoprotein cholesterol.CC BY-NC-ND · PubMed Central
Fig. 4 Overall effects of GLP-1 RAs. Overall effects of A cancer outcomes; B renal outcomes; C respiratory outcomes; D other outcomes. All included meta-analyses were based on RCTs and analyzed using random-effects models. All statistical tests were two-sided, and no adjustments were made for multiple comparisons. Effect estimates are shown as pooled effect sizes with 95% confidence intervals. Symbols (*) and (F) within the figure refer to additional details explained directly in the panel. NR not reported, IG intervention group, CG control group, VL very low, L low, M moderate, H high, AD Alzheimer’s disease, MCI mild cognitive impairment, T2DM type 2 diabetes mellitus, CAD coronary artery disease, CKD chronic kidney disease, MDRS Mattis Dementia Rating Scale, UPDRS Unified Parkinson’s Disease Rating Scale.
Fig. 4 Overall effects of GLP-1 RAs. Overall effects of A cancer outcomes; B renal outcomes; C respiratory outcomes; D other outcomes. All included meta-analyses were based on RCTs and analyzed using random-effects models. All statistical tests were two-sided, and no adjustments were made for multiple comparisons. Effect estimates are shown as pooled effect sizes with 95% confidence intervals. Symbols (*) and (F) within the figure refer to additional details explained directly in the panel. NR not reported, IG intervention group, CG control group, VL very low, L low, M moderate, H high, AD Alzheimer’s disease, MCI mild cognitive impairment, T2DM type 2 diabetes mellitus, CAD coronary artery disease, CKD chronic kidney disease, MDRS Mattis Dementia Rating Scale, UPDRS Unified Parkinson’s Disease Rating Scale.CC BY-NC-ND · PubMed Central
Fig. 5 Overall effects of GLP-1 RAs on mortality and AEs. All included meta-analyses were based on RCTs and analyzed using random-effects models. All statistical tests were two-sided, and no adjustments were made for multiple comparisons. Effect estimates are shown as pooled effect sizes with 95% confidence intervals. Symbols (*) and (F) within the figure refer to additional details explained directly in the panel. NR not reported, IG intervention group, CG control group, VL very low, L low, M moderate, H high, AE adverse event, CV cardiovascular, PCOS polycystic ovary syndrome, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus, COVID-19 coronavirus disease 2019, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2.
Fig. 5 Overall effects of GLP-1 RAs on mortality and AEs. All included meta-analyses were based on RCTs and analyzed using random-effects models. All statistical tests were two-sided, and no adjustments were made for multiple comparisons. Effect estimates are shown as pooled effect sizes with 95% confidence intervals. Symbols (*) and (F) within the figure refer to additional details explained directly in the panel. NR not reported, IG intervention group, CG control group, VL very low, L low, M moderate, H high, AE adverse event, CV cardiovascular, PCOS polycystic ovary syndrome, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus, COVID-19 coronavirus disease 2019, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Research works printed but not linked: 1

  1. Science’s 2023 Breakthrough of the Year: weight loss drugs with a real shot at fighting obesity. https://www.science.org/content/article/breakthrough-of-the-year-2023.

Cited by

See all 29

Metadata

Authors
Kong, F., Zhao, Y., Zhang, W., Wang, X., Wu, T., Zhou, Z., Xu, Y., Xia, L., & Sun, T.
Affiliations
Chengdu University of Traditional Chinese Medicine (CN)
Corresponding author
  • Xu, Ying
  • Xia, Lina
  • Sun, Tao
Venue
Nature Communications
Published
2026-01-07
Volume
17
Issue
1
Pages
972-972
ISSN
2041-1723 (ISSN-L)
OpenAlex
W7118511453
Cited by
29
References
58
Citations by year
2026: 29
FWCI
30.83
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Chengdu University of Traditional Chinese Medicine
  • Jiangxi University of Traditional Chinese Medicine
  • Chengdu University
  • Maryland Population Research Center, University of Maryland
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
GLP-1 receptor agonists, type 2 diabetes, cardiovascular outcomes, renal outcomes, respiratory outcomes, cognitive function, fracture risk, all-cause mortality, adverse events, diabetic ketoacidosis, diabetic retinopathy, gastrointestinal adverse effects, treatment discontinuation, off-label drug use
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Meta-Analysis as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases. https://app.cochat.ai/papers/10.1038/s41467-025-67701-9
The paper
Kong, F., Zhao, Y., Zhang, W., Wang, X., Wu, T., Zhou, Z., Xu, Y., Xia, L., & Sun, T. (2026). Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases. Nature Communications. https://doi.org/10.1038/s41467-025-67701-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.